Your browser doesn't support javascript.
loading
Biomarker Discovery and Validation: Statistical Considerations.
Ou, Fang-Shu; Michiels, Stefan; Shyr, Yu; Adjei, Alex A; Oberg, Ann L.
Afiliación
  • Ou FS; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Electronic address: ou.fang-shu@mayo.edu.
  • Michiels S; Department of Biostatistics and Epidemiology, Gustave Roussy, Oncostat U1018, CESP, Inserm, Université Paris-Saclay, labelel Ligue Contre le Cancer, Villejuif, France.
  • Shyr Y; Department of Biostatistics, Vanderbilt University, Nashville, Tennessee.
  • Adjei AA; Department of Oncology, Mayo Clinic, Rochester, Minnesota.
  • Oberg AL; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
J Thorac Oncol ; 16(4): 537-545, 2021 04.
Article en En | MEDLINE | ID: mdl-33545385
ABSTRACT
Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Investigación Biomédica / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Investigación Biomédica / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2021 Tipo del documento: Article
...